A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia Authors: Ricardo D Parrondo, Sikander Ailawadhi, Betsy R Knopf, Ashley Zimmerman, Carly J Kasik, Dustin Chapin, Keisha Heslop, Vivek Roy, Aneel Paulus, Asher A Chanan-Khan Published: 2026 Dear Editor, Due to the advent of novel targeted therapies such as BTK inhibitors and BCL-2 inhibitors, the survival outcomes of patients with chronic lymphocytic leukemia (CLL) have improved considerably over the last decade [1–4]. In the RESONATE 2 trial, single agent ibrutinib resulted in a 9-year progression free survival (PFS) rate of 50% [4]. Despite the impressive long-term disease control afforded by covalent BTK inhibitors like ibrutinib, many patients eventually develop drug resistance commonly due to the development of BTK mutations (C481S) or mutations in PLCγ2 that are immediately downstream of BTK [5]. While other options exist post-progression on covalent BTK inhibitors such as non-covalent BTK inhibitors and BCL-2 inhibitors, patients ultimately develop resistance to these therapies and develop relapsed and refractory disease [6, 7]. CD38 expression (>30%) in CLL has been associated with enhanced B-cell signaling and clonal aggressiveness and overall worse clinical outcomes as compared to CD38 negative (<30%) CLL [8, 9]. Our preclinical data have shown that the anti-CD38 monoclonal antibody (mAb) daratumumab (Dara) resulted in antibody-dependent cellular cytotoxicity, complement dependent cytotoxicity, and antibody-dependent cellular phagocytosis against both CD38+ and CD38- CLL cells Ex Vivo and also modulated the immune microenvironment by decreasing regulatory T cells and increasing effector T cells with CLL-specific cytolytic activity [10]. These pre-clinical results merit further evaluation of Dara for the treatment of CLL. Herein, we present the results of a prospective phase II study evaluating the efficacy of Dara+ ibrutinib in patients with relapsed/refractory (R/R) CLL including ibrutinib exposed and ibrutinib naive patients (NCT04230304). This study was approved by the Institutional Review Board at Mayo Clinic Florida. Key inclusion criteria included R/R CLL after at least 1 prior line of therapy, presence of measurable disease, and ECOG of ≤2. BTK inhibitor exposed patients were allowed if they were either taken off a BTK inhibitor for any reason other than grade 4 toxicity, were refractory to BTK inhibitor or were currently on a BTK inhibitor and failed to achieve complete response (CR) after 12 cycles or achieved 30%. Six patients were ibrutinib exposed (one was ibrutinib refractory and five had previously received time-limited ibrutinib on a clinical trial evaluating 6 cycles of obinutuzumab followed by time-limited ibrutinib therapy [36 months]) [12] and 2 patients were ibrutinib naïve. Patients received a median of 2 [1–5] prior lines of therapy. Patients received a median of 24 cycles (range: 1–25) of Dara+ ibrutinib therapy. The ORR after 6 cycles of Dara + ibrutinib was 37.5%. The ORR was 100.0% in ibrutinib naïve and was 16.7% in ibrutinib exposed. Three patients achieved PR and 4 achieved stable disease (SD). One patient discontinued treatment after one cycle (due to treatment intolerance to IV Dara) and was not evaluated for response. The ORR (at any point during treatment) to Dara + ibrutinib was 50.0%. The ORR was 100.0% in ibrutinib naïve and was 33.3% in ibrutinib exposed. Four achieved PR and 3 achieved SD. One patient had deepening of response; 1 patient went from SD to PR, and 4 patients had no change in response. No patients achieved MRD negativity in peripheral blood or in the bone marrow. There were 5 patients that progressed, and one patient died due to an unknown reason 6 months after patient came off study and was lost to follow-up. Four of the progressed patients are a part of the ibrutinib exposed cohort with progression times of 23.9, 24.3, 28.2, and 32.2 months. One patient in the ibrutinib naïve cohort progressed at 28.4 months. Median follow-up for patients still alive is 46.0 mo (range: 25.8–47.2). Duration of response for the 4 patients who achieved a PR was 17.3, 17.4, 18.1, and 12.2 months. AEs are shown in Table 2. Table 1Patient baseline characteristics.CohortExposed (N = 6)Naïve (N = 2)Total (N = 8)Sex, n (%)Female1 (16.7%)2 (100.0%)3 (37.5%)Male5 (83.3%)0 (0.0%)5 (62.5%)Age, Median (Range)69.5 (62.0, 75.0)60.5 (60.0, 61.0)66.5 (60.0, 75.0)Rai Stage at Diagnosis, n (%)Stage 03 (50.0%)1 (50.0%)4 (50.0%)Stage II3 (50.0%)0 (0.0%)3 (37.5%)Stage III0 (0.0%)1 (50.0%)1 (12.5%)FISH Del 11q, n (%)N4 (80.0%)2 (100.0%)6 (85.7%)Y1 (20.0%)0 (0.0%)1 (14.3%)Missing101FISH Trisomy 12, n (%)N3 (60.0%)1 (50.0%)4 (57.1%)Y2 (40.0%)1 (50.0%)3 (42.9%)Missing101FISH Del13q, n (%)N2 (40.0%)1 (50.0%)3 (42.9%)Y3 (60.0%)1 (50.0%)4 (57.1%)Missing101FISH Del17p, n (%)N5 (100.0%)1 (50.0%)6 (85.7%)Y0 (0.0%)1 (50.0%)1 (14.3%)Missing101FISH Other, n (%)N4 (80.0%)2 (100.0%)6 (85.7%)Y1 (20.0%)0 (0.0%)1 (14.3%)Missing101IgHV Gene Mutation Status, n (%)Mutated1 (16.7%)0 (0.0%)1 (12.5%)Unmutated5 (83.3%)2 (100.0%)7 (87.5%)CD38 Expression > 30%, n (%)Negative2 (33.3%)0 (0.0%)2 (25.0%)Not done3 (50.0%)1 (50.0%)4 (50.0%)Positive1 (16.7%)1 (50.0%)2 (25.0%)ZAP-70 Expression > 20%, n (%)Negative2 (33.3%)0 (0.0%)2 (25.0%)Not done3 (50.0%)2 (100.0%)5 (62.5%)Positive1 (16.7%)0 (0.0%)1 (12.5%)Prior Lines of Therapy, Median (Range)2.0 (2.0, 5.0)1.0 (1.0, 1.0)2.0 (1.0, 5.0)Cycles of Dara+Ibrut combo, Median (Range)24.0 (1.0, 25.0)24.5 (24.0, 25.0)24.0 (1.0, 25.0) Patient baseline characteristics. Table 2Adverse events.Adverse eventsGrade123N%N%N%TypeCohort466.7Anemia122100.0Bruising1466.722100.0Fatigue1350.02150.0150.0Platelet count decreased1233.3116.72150.0Hypertension1233.32150.0Lymphocyte count increased1116.72150.0150.0Rash maculo-papular1233.3116.7Abdominal pain1116.7Arthralgia2150.0Atrial fibrillation1116.7Bacteremia1116.7Creatinine increased2150.0Epistaxis1116.7Fever1116.7Headache1116.7Infections and infestations - Oth spec1116.7Infusion related reaction1116.7Lymphocyte count decreased1116.7Muscle cramp2150.0Myalgia2150.0Nausea1116.7Neutrophil count decreased2150.0Pneumonitis1116.7Sepsis1116.7Skin and subcut tissue disord - Oth spec1116.7Skin infection1116.7Vomiting1116.7 Adverse events. With only a small number of patients treated, safety and efficacy conclusions could not be drawn from the combination of Dara + ibrutinib in patients with R/R CLL and the primary endpoint could not be formally evaluated in this study. Nonetheless, the combination of Dara+ ibrutinib yielded an ORR of 100% and 33.3% (all PRs) in the limited number of ibrutinib-naïve and ibrutinib-exposed patients respectively. Responses were relatively short-lived as the patients who achieved PR had a duration of response ranging from 12-18 months. ORR were lower than expected considering that the majority of patients had received prior fixed-duration ibrutinib and were not truly ibrutinib refractory; in the phase II CAPTIVATE study where patients received fixed duration venetoclax + ibrutinib, retreatment with ibrutinib at the time of PD resulted in an ORR of 86% [13]. While we did not test for BTK mutations, it is plausible that the ibrutinib-exposed patients, the majority of which had previously received 3 years of ibrutinib, may have developed BTK-resistance mutations and this may explain the low ORR and duration of responses seen when re-treated with ibrutinib. In the CAPTIVATE study there was no evidence of BTK mutations in patients who received 15 cycles of ibrutinib in combination with venentoclax [14]. In the FLAIR study, patients received either ibrutinib or ibrutinib plus rituximab until disease progression and 13% of patients had a BTK/PLCG2 mutations at disease progression and 46.6% (n = 7/15) acquired non- BTK/ PLCG2 mutations at disease progression after a median follow-up of 44 mo on ibrutinib [15]. There did not appear to be additional toxicity with the addition of Dara to ibrutinib and the majority of AEs were low grade AEs that have previously been reported with ibrutinib such as bruising, fatigue, anemia, and maculopapular rash. While there was one patient who discontinued trial treatment due to intolerance to IV Dara, once the protocol was amended and allowed subQ Dara, there was no additional Dara intolerance in any patient. A phase II study evaluated the combination of Dara + ibrutinib in p53-aberrant, ibrutinib-naïve R/R CLL patients and the study was suspended due to slow accrual after 29 out of the planned 44 patients had been accrued. ORR and CR rates were 78% and 3.7%, respectively. With a median follow-up of 20.2 months, median PFS and OS were 27.1 and 33.5 months, respectively [16]. While slow accrual hindered our study’s ability to significantly evaluate the efficacy of Dara + ibrutinib in R/R CLL, strong pre-clinical data demonstrated that the combination of Dara + ibrutinib induces immune-effector mediated and direct apoptosis of CLL cells irrespective of CD38 expression status and that targeting CD38 on CLL cells leads to downregulation of BCR-associated proteins in CLL cells and which can be further amplified through simultaneous inhibition of BTK with ibrutinib [17]. However, given the advances in the field with development of next generation BTK degraders, cellular therapies, bispeicifc antibodies, and other small molecule inhibitors [18], it is unlikely that there will be any further exploration of Dara in CLL. Supplementary information Trial Protocol Acknowledgements We thank all patients and the data collection team who participated in this study. Author contributions Asher A. Chanan-Khan, Sikander Ailawadhi, Ricardo D. Parrondo, and Aneel Paulus designed the study. Ricardo D. Parrondo wrote the manuscript. Knopf performed the statistical analysis. Ricardo D. Parrondo, Vivek Roy, Betsy R. Knopf, Ashley Zimmerman, Keisha Heslop, Carly J. Kasik, Dustin Chapin collected/analyzed the data for the study. All authors critically revised the manuscript and approved the final version. Funding Funded by Janssen Pharmaceuticals. This work was also supported by a grant from the NIH (RO1 CA233790-04). Competing interests BRK, AZ, CJK, DC, AP, and VR have no conflicts of interest to declare. RDP serves on the advisory board for Sanofi Aventis, Bristol Myers Squibb and Astra Zeneca and has received research funding from Bristol Myers Squibb Foundation, Beigene, and GlaxoSmithKline. SA has provided consultancy for Celgene, Amgen, Janssen and Takeda, and has received research funding from Pharmacyclics, Cellectar and Janssen. AAC-K has received research funding from Xencor Pharmacyclics, Merck, Janssen, Ascentage and Millennium. Ethics statement The study protocol and all amendments were reviewed and approved by the Institutional Review Board at Mayo Clinic Florida (IRB #19-001475). The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles originating from the Declaration of HelsInformed consentinki, and study site-specific regulations. Informed consent All participants signed written informed-consent forms. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information The online version contains supplementary material available at 10.1038/s41408-026-01497-9. References Associated Data Supplementary Materials Trial Protocol